Characterization of URST1 as a biomarker and therapeutic target for oral cancer.

Authors

null

Atsushi Takano

Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Atsushi Takano , Yoshihiro Yoshitake , Masanori Shinohara , Yataro Daigo

Organizations

Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, Department of Oral and Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, Dep. of Med. Oncol. & Cancer Ctr., Ctr. for Advanced Med. against Cancer, Shiga Univ. of Med. Sci., Otsu, Japan

Research Funding

No funding received

Background: Cancer-specific oncoproteins are expected to be useful for the development of novel biomarkers and therapeutic targets for oral cancers. Methods: We screened candidate oncoproteins as follows: i) Identification of up-regulated genes in oral cancers by gene microarray, ii) Validation of clinicopathological significance of their protein expression by tissue microarray, iii) Examination of their growth effect on cancer cells by siRNA/small molecule compounds, iv) Elucidation of their tumor promoting effects by enforced gene expression. Results: Using above mentioned approach, we identified URST1 (Up-regulated solid tumor 1) as a candidate. Immunohistochemical staining showed that URST1 protein expression was observed in 110 (71.0%) of 155 oral cancers that had undergone curative surgery. In addition, high level of URST1 expression was associated with poor prognosis for oral cancer patients (P = 0.0021, by log-rank test) and it was an independent prognostic factor. Reduction of URST1 expression by siRNA specific for URST1 significantly suppressed the growth of oral cancer cell lines and induced G2/M arrest as detected by flowcytometry and time lapse imaging. In contrast, enforced expression of URST1 enhanced the growth of oral cancer cells. The growth of oral cancer cells were inhibited by the URST1 inhibitor. Microarray analysis coupled with siRNAs for URST1 suggested various URST1-related oncogenic pathways in oral cancer cells. Conclusions: URST1 is a possible prognostic biomarker and therapeutic target for oral cancer.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Other Head and Neck Cancer (Salivary, Thyroid)

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e18092)

DOI

10.1200/JCO.2022.40.16_suppl.e18092

Abstract #

e18092

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Annual Meeting

Impact on biomarker documentation in community oncology by optimizing clinical decision support.

First Author: Daniel Rubin

Abstract

2019 ASCO Annual Meeting

Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer.

First Author: Atsushi Takano

Abstract

2023 ASCO Quality Care Symposium

Awareness of biomarker test timing and purpose in patients with non-small cell lung cancer (NSCLC).

First Author: Nisha Anjali Mohindra

First Author: Julia R. Trosman